ADC Therapeutics Amends Royalty Purchase Agreement with HealthCare Royalty
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy ADCT?
Source: PRnewswire
- Agreement Terms Update: ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, reducing the change of control payment from $750 million to $150 million until the end of 2027, and $200 million thereafter, enhancing the company's strategic flexibility.
- Warrant Grant: As part of the agreement, HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, with a lock-up period until the end of 2027, reflecting confidence in ZYNLONTA's potential.
- Optimistic Market Outlook: The potential peak revenue for ZYNLONTA in the U.S. could reach between $600 million and $1 billion, indicating strong confidence in future growth, particularly starting in 2027.
- Clinical Data Support: With multiple clinical data readouts expected, ADC Therapeutics is optimistic about ZYNLONTA's best-in-class potential in treating diffuse large B-cell lymphoma, which is anticipated to unlock significant market value for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.100
Low
5.00
Averages
7.33
High
10.00
Current: 4.100
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADC Therapeutics Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: ADC Therapeutics will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, where CEO Ameet Mallik will present at 11:50 a.m. EST, which is expected to attract investor attention and enhance the company's visibility.
- One-on-One Meeting Opportunities: At the Jefferies Biotech on the Beach Summit on March 11, 2026, ADC Therapeutics will hold one-on-one meetings, a format that helps establish closer connections with potential investors, potentially facilitating future financing opportunities.
- Product Development Highlights: ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission, indicating the company's innovative capabilities in the field of antibody-drug conjugates, which is expected to drive sales growth and enhance market competitiveness.
- Global Business Layout: Headquartered in Lausanne, Switzerland, with operations in New Jersey, the company demonstrates its globalization strategy aimed at driving innovation in ADC development and further expanding its international market share.
See More
ADC Therapeutics Amends Royalty Purchase Agreement with HealthCare Royalty
- Agreement Terms Update: ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, reducing the change of control payment from $750 million to $150 million until the end of 2027, and $200 million thereafter, enhancing the company's strategic flexibility.
- Warrant Grant: As part of the agreement, HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, with a lock-up period until the end of 2027, reflecting confidence in ZYNLONTA's potential.
- Optimistic Market Outlook: The potential peak revenue for ZYNLONTA in the U.S. could reach between $600 million and $1 billion, indicating strong confidence in future growth, particularly starting in 2027.
- Clinical Data Support: With multiple clinical data readouts expected, ADC Therapeutics is optimistic about ZYNLONTA's best-in-class potential in treating diffuse large B-cell lymphoma, which is anticipated to unlock significant market value for the company.
See More
ADC Therapeutics Amends Royalty Purchase Agreement with HealthCare Royalty
- Strategic Flexibility Enhanced: ADC Therapeutics amended its royalty purchase agreement with HealthCare Royalty, reducing the change of control payment from $750 million to $150 million, and $200 million thereafter, thereby providing greater strategic flexibility that is expected to facilitate future growth.
- Equity Incentive Arrangement: Under the new agreement, HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, with a lock-up period until the end of 2027, incentivizing continued support for ADC's long-term development.
- Revenue Potential Outlook: ADC Therapeutics anticipates that ZYNLONTA could achieve peak annual revenues of $600 million to $1 billion in the U.S., based on confidence in its clinical data, which is expected to drive significant growth beginning in 2027.
- Market Confidence Strengthened: HealthCare Royalty expressed confidence in ZYNLONTA's long-term potential, believing that upcoming clinical data will further validate its value in treating diffuse large B-cell lymphoma, potentially unlocking significant market opportunities for ADC Therapeutics.
See More
ADC Therapeutics Grants Stock Options to New Employees
- Employee Incentive Program: On February 2, 2026, ADC Therapeutics granted stock options for 308,000 common shares to seven new employees as a significant inducement for their employment, aimed at motivating them to contribute meaningfully to the company's success.
- Grant Details: The stock options will vest 25% on the first anniversary of the grant date, with 1/48th vesting monthly thereafter, ensuring full vesting by the fourth anniversary, which encourages employee retention.
- Compliance Assurance: The grants were made in reliance on the employment inducement exemption under NYSE's Listed Company Manual Rule 303A.08, ensuring that the company meets regulatory requirements while incentivizing its workforce.
- Company Background: ADC Therapeutics focuses on the development of antibody-drug conjugates (ADCs), with its product ZYNLONTA receiving accelerated approval from the FDA, highlighting the company's leadership in innovative drug development.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, which benefits Oncolytics Biotech by attracting increased investor interest.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive late-stage clinical trial experience to drive complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer patients, the combination of pelareorep and chemotherapy achieved a 33% response rate, significantly surpassing the traditional 6-11% response rate, showcasing its competitive edge and potential commercial value in the market.
- Phase 3 Trial Design Approved: Oncolytics Biotech has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of its registration trial in this notoriously difficult-to-treat area, further solidifying its market position.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA drug approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, positioning Oncolytics Biotech to benefit from increased capital inflow.
- Leadership Enhancement: Oncolytics Biotech announced the hiring of two key executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, whose extensive experience will enhance the company's execution in complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer, pelareorep combined with chemotherapy achieved a 33% response rate, three times higher than traditional treatments, showcasing its competitive edge and likely attracting more investor interest.
- Regulatory Approval Secured: Oncolytics Biotech has received FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial planned for this challenging disease, further solidifying its market position.
See More
ADC Therapeutics Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: ADC Therapeutics will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, where CEO Ameet Mallik will present at 11:50 a.m. EST, which is expected to attract investor attention and enhance the company's visibility.
- One-on-One Meeting Opportunities: At the Jefferies Biotech on the Beach Summit on March 11, 2026, ADC Therapeutics will hold one-on-one meetings, a format that helps establish closer connections with potential investors, potentially facilitating future financing opportunities.
- Product Development Highlights: ADC Therapeutics' ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission, indicating the company's innovative capabilities in the field of antibody-drug conjugates, which is expected to drive sales growth and enhance market competitiveness.
- Global Business Layout: Headquartered in Lausanne, Switzerland, with operations in New Jersey, the company demonstrates its globalization strategy aimed at driving innovation in ADC development and further expanding its international market share.
See More
ADC Therapeutics Amends Royalty Purchase Agreement with HealthCare Royalty
- Agreement Terms Update: ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, reducing the change of control payment from $750 million to $150 million until the end of 2027, and $200 million thereafter, enhancing the company's strategic flexibility.
- Warrant Grant: As part of the agreement, HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, with a lock-up period until the end of 2027, reflecting confidence in ZYNLONTA's potential.
- Optimistic Market Outlook: The potential peak revenue for ZYNLONTA in the U.S. could reach between $600 million and $1 billion, indicating strong confidence in future growth, particularly starting in 2027.
- Clinical Data Support: With multiple clinical data readouts expected, ADC Therapeutics is optimistic about ZYNLONTA's best-in-class potential in treating diffuse large B-cell lymphoma, which is anticipated to unlock significant market value for the company.
See More
ADC Therapeutics Amends Royalty Purchase Agreement with HealthCare Royalty
- Strategic Flexibility Enhanced: ADC Therapeutics amended its royalty purchase agreement with HealthCare Royalty, reducing the change of control payment from $750 million to $150 million, and $200 million thereafter, thereby providing greater strategic flexibility that is expected to facilitate future growth.
- Equity Incentive Arrangement: Under the new agreement, HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, with a lock-up period until the end of 2027, incentivizing continued support for ADC's long-term development.
- Revenue Potential Outlook: ADC Therapeutics anticipates that ZYNLONTA could achieve peak annual revenues of $600 million to $1 billion in the U.S., based on confidence in its clinical data, which is expected to drive significant growth beginning in 2027.
- Market Confidence Strengthened: HealthCare Royalty expressed confidence in ZYNLONTA's long-term potential, believing that upcoming clinical data will further validate its value in treating diffuse large B-cell lymphoma, potentially unlocking significant market opportunities for ADC Therapeutics.
See More
ADC Therapeutics Grants Stock Options to New Employees
- Employee Incentive Program: On February 2, 2026, ADC Therapeutics granted stock options for 308,000 common shares to seven new employees as a significant inducement for their employment, aimed at motivating them to contribute meaningfully to the company's success.
- Grant Details: The stock options will vest 25% on the first anniversary of the grant date, with 1/48th vesting monthly thereafter, ensuring full vesting by the fourth anniversary, which encourages employee retention.
- Compliance Assurance: The grants were made in reliance on the employment inducement exemption under NYSE's Listed Company Manual Rule 303A.08, ensuring that the company meets regulatory requirements while incentivizing its workforce.
- Company Background: ADC Therapeutics focuses on the development of antibody-drug conjugates (ADCs), with its product ZYNLONTA receiving accelerated approval from the FDA, highlighting the company's leadership in innovative drug development.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, which benefits Oncolytics Biotech by attracting increased investor interest.
- Leadership Enhancement: Oncolytics Biotech appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President of Biostatistics, both bringing extensive late-stage clinical trial experience to drive complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer patients, the combination of pelareorep and chemotherapy achieved a 33% response rate, significantly surpassing the traditional 6-11% response rate, showcasing its competitive edge and potential commercial value in the market.
- Phase 3 Trial Design Approved: Oncolytics Biotech has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of its registration trial in this notoriously difficult-to-treat area, further solidifying its market position.
See More
Oncolytics Biotech Strengthens Leadership Amid FDA Approval Surge
- Surge in FDA Approvals: In 2025, over 50 FDA drug approvals were granted, with 20 in Q4 alone, indicating strong institutional confidence in late-stage platforms, positioning Oncolytics Biotech to benefit from increased capital inflow.
- Leadership Enhancement: Oncolytics Biotech announced the hiring of two key executives, John McAdory as EVP of Strategy and Operations and Yujun Wu as VP of Biostatistics, whose extensive experience will enhance the company's execution in complex multi-country registration trials.
- Impressive Clinical Data: In colorectal cancer, pelareorep combined with chemotherapy achieved a 33% response rate, three times higher than traditional treatments, showcasing its competitive edge and likely attracting more investor interest.
- Regulatory Approval Secured: Oncolytics Biotech has received FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial planned for this challenging disease, further solidifying its market position.
See More
